Active Stocks
Fri Sep 29 2023 15:59:14
  1. Tata Steel share price
  2. 129 1.78%
  1. NTPC share price
  2. 245.65 3.3%
  1. Power Grid Corporation Of India share price
  2. 199.85 -0.45%
  1. State Bank Of India share price
  2. 598.7 1.48%
  1. Wipro share price
  2. 406.25 0.11%
Business News/ Markets / Stock Markets/  Multibagger small-cap stock hits upper circuit on two days in a row after Q4 results

Multibagger small-cap stock hits upper circuit on two days in a row after Q4 results

Multibagger small-cap stock has surged over 10% in the last two days after announcing Q4 results

Multibagger stock: MSME pharma company's net profit rose by 70% YoY to  ₹5.13 crore in Q4FY23.Premium
Multibagger stock: MSME pharma company's net profit rose by 70% YoY to 5.13 crore in Q4FY23.

Multibagger stock: Shares of Kilitch Drugs (India) Ltd are one of those stocks that have delivered strong upside movement in post-Covid rebound. This small-cap stock has risen from around 82 to 215 apiece levels in last two years, delivering to the tune of 250 per cent rise in this time. The multibagger stock is in news again as the small-cap stock has been hitting upper circuit for the last two days after announcement of fourth quarter results.

After declaration of Q4 results on Wednesday evening, the multibagger stock hit 5 per cent upper circuit on Thursday session within few minutes of stock market's opening bell. The small-cap stock extended its rally on Friday and went on to hit 5 per cent upper circuit after hitting intraday high of 215.70 apiece on NSE. So, in last two days after the announcement of Q4 results, the small-cap multibagger stock has surged over 10 per cent in last two days.

Kilitch Drugs Q4 results 2023

In Q4FY23, Kilitch Drugs (India) Ltd reported net profit of 5.13 crore, which is near 70 per cent higher from its net profit in the corresponding period in the previous financial year. Its EBITDA grew by over 71 per cent YoY to 8.12 crore in January to March 2023 quarter. India's leading MSME multinational manufacturer's total revenue grew by over 35 per cent YoY to 43.28 crore in the recently ended March 2023 quarter.

In recently ended financial year 2022-23, the MSME pharma company reported over 49 per cent YoY rise in net profit at 15.72 crore. The YoY EBITDA of the company in FY23 grew by around 40 per cent to 21.77 crore.

Speaking on the Q4 results of the company during guidance, Mukund Mehta, Managing Director of Kilitch Drugs (India) Limited said, “We experienced a remarkable 69.87 per cent increase in net profit, which can be attributed to the splendid demand for our products during this period. I am particularly pleased with the results of our efforts to improve pricing and exercise rigorous cost control, which led to an impressive ~400 basis point jump in our EBITDA margin. This accomplishment reflects the dedication and hard work of our team."

Shares of Kilitch Drugs (India) Ltd are available for trade on both NSE and BSE. Its current trade volume on NSE is 14,456 and around three hours of trade is still left today. Its current market cap is 332 crore. The multibagger small-cap stock made 52-week of 231.85 apiece on NSE whereas it has made 52-week low of 125 per share on NSE.

"Exciting news! Mint is now on WhatsApp Channels 🚀 Subscribe today by clicking the link and stay updated with the latest financial insights!" Click here!

Asit Manohar
Chief Content Producer at Live Mint Digital Team
Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Updated: 02 Jun 2023, 12:56 PM IST
Next Story
Recommended For You

Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

Let’s get started
Switch to the Mint app for fast and personalized news - Get App